Fetzima (levomilnacipran) is primarily indicated for the treatment of which condition?

Fetzima, also known as levomilnacipran, is primarily indicated for the treatment of Major Depressive Disorder (MDD). It is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain, which are neurotransmitters that play a significant role in mood regulation. This dual action helps improve symptoms of depression, making it useful in clinical settings for individuals diagnosed with MDD.

While other disorders like Generalized Anxiety Disorder, Bipolar Disorder, and Post-Traumatic Stress Disorder may involve similar symptoms or require pharmacological intervention, Fetzima has not been specifically validated in clinical studies for these conditions. The focus of its indication is firmly on Major Depressive Disorder, thus solidifying its role in the treatment for individuals experiencing this particular mental health issue.